Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 51 results
Filters: Author is Haas, David W  [Clear All Filters]
Found 51 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Haas DW, Koletar SL, Laughlin L, et al. "Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir." J. Acquir. Immune Defic. Syndr.. 2009;50(3):290-3.
Haas DW, Geraghty DE, Andersen J, et al. "Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study." J. Infect. Dis.. 2006;194(8):1098-107.
Haas DW, Bartlett JA, Andersen JW, et al. "Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration." Clin. Infect. Dis.. 2006;43(6):783-6.
Haas DW. "Human genetic variability and HIV treatment response." Curr HIV/AIDS Rep. 2006;3(2):53-8.
Haas DW, Mootsikapun P, Ruxrungtham K, Podzamczer D. "Clinical perspectives on human genetic screening to prevent nevirapine toxicity." Per Med. 2012;9(7):773-782.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Holzinger ER, Grady B, Ritchie MD, et al. "Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants." Pharmacogenet. Genomics. 2012;22(12):858-67.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.
Hulgan T, Hughes M, Sun X, et al. "Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study." J. Acquir. Immune Defic. Syndr.. 2006;42(4):450-4.
Hulgan T, Donahue JP, Smeaton L, et al. "Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors." Eur. J. Clin. Pharmacol.. 2009;65(11):1081-8.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Hulgan T, Stein JH, Cotter BR, et al. "Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation." AIDS Res. Hum. Retroviruses. 2013;29(10):1293-9.

Pages